United States Patent Granted to Biotranex for MDR3cyteŽ Assay

Wednesday, May 15, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Biotranex LLC, an innovative biotech service company at the forefront of developing and offering drug transporter assays, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company United States patent number 10,280,401, which covers its novel multidrug resistance protein 3 (MDR3 or ABCB4) inhibition assay that is marketed as MDR3cyteŽ.

MONMOUTH JUNCTION, N.J., May 15, 2019 /PRNewswire-PRWeb/ -- Biotranex LLC, an innovative biotech service company at the

forefront of developing and offering drug transporter assays, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company United States patent number 10,280,401, which covers its novel multidrug resistance protein 3 (MDR3 or ABCB4) inhibition assay that is marketed as MDR3cyteŽ. The patent is entitled "Method for Measuring Phosphatidylcholine Transport and/or Formation Activity."

The MDR3 hepatic transport protein is responsible for biliary secretion of phosphatidylcholine (PC). Dysfunction of human MDR3 is associated with a wide spectrum of liver diseases, such as progressive familial intrahepatic cholestasis type 3 (PFIC3), intrahepatic cholestasis of pregnancy (ICP), low-phospholipid-associated cholelithiasis, primary biliary cirrhosis, cholangiocarcinoma, and drug-induced liver injury (DILI).

This physiologically relevant hepatocyte-based system, MDR3cyteŽ, allows for measurement of MDR3 inhibition by chemical entities, drugs and drug candidates in human as well as animal hepatocyte preparations. The MDR3cyteŽ assay is suitable for use in an early screening strategy or in more detailed mechanistic investigations.

"The role that inhibition of liver transporters, including MDR3, plays in drug-induced liver injury is only recently being appreciated in the pharmaceutical and biotech industries," states Dr. Kan He. The MDR3cyteŽ assay employs a platform using human or animal hepatocytes in a multi-well plate format with liquid chromatography-mass spectrometry quantification. The assay is reproducible, sensitive, flexible, robust, and possesses a wide dynamic concentration range.

Dr. He further states, "We are pleased to introduce this validated MDR3cyteŽ assay, which combined with our BSEPcyteŽ and Bilirubincyte™ assays, offers a more expansive profile of a test agent's ability to cause DILI."

Biotranex LLC is an innovative biotech service company that commercializes novel and proprietary assays for assessing hepatic transport, cholestasis, and drug-induced liver injury potential. Biotranex offers an array of drug metabolism, transporter, pharmacokinetic, and analytic services. The company is located near Princeton, New Jersey, in Monmouth Junction. http://www.biotranex.com.

Contacts: Kan He, Ph.D. - President Khe(at)biotranex(dot)com (732) 230-3062

Thomas F. Woolf, Ph.D. - Senior Vice President Twoolf(at)biotranex(dot)com (732) 230-3062

 

SOURCE Biotranex LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store